Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Section of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Front Endocrinol (Lausanne). 2024 Mar 26;15:1333778. doi: 10.3389/fendo.2024.1333778. eCollection 2024.
There has been a major increase in Type 2 diabetes and obesity in many countries, and this will lead to a global public health crisis, which not only impacts on the quality of life of individuals well but also places a substantial burden on healthcare systems and economies. Obesity is linked to not only to type 2 diabetes but also cardiovascular diseases, musculoskeletal disorders, and certain cancers, also resulting in increased medical costs and diminished quality of life. A number of studies have linked changes in gut in obesity development. Dysbiosis, a deleterious change in gut microbiota composition, leads to altered intestinal permeability, associated with obesity and Type 2 diabetes. Many factors affect the homeostasis of gut microbiota, including diet, genetics, circadian rhythms, medication, probiotics, and antibiotics. In addition, bariatric surgery induces changes in gut microbiota that contributes to the metabolic benefits observed post-surgery. Current obesity management strategies encompass dietary interventions, exercise, pharmacotherapy, and bariatric surgery, with emerging treatments including microbiota-altering approaches showing promising efficacy. While pharmacotherapy has demonstrated significant advancements in recent years, bariatric surgery remains one of the most effective treatments for sustainable weight loss. However, access to this is generally limited to those living with severe obesity. This underscores the need for non-surgical interventions, particularly for adolescents and mildly obese patients. In this comprehensive review, we assess longitudinal alterations in gut microbiota composition and functionality resulting from the two currently most effective anti-obesity treatments: pharmacotherapy and bariatric surgery. Additionally, we highlight the functions of gut microbiota, focusing on specific bacteria, their metabolites, and strategies for modulating gut microbiota to prevent and treat obesity. This review aims to provide insights into the evolving landscape of obesity management and the potential of microbiota-based approaches in addressing this pressing global health challenge.
在许多国家,2 型糖尿病和肥胖症的发病率都大幅上升,这将导致一场全球公共健康危机,不仅严重影响个人的生活质量,还给医疗体系和经济带来沉重负担。肥胖不仅与 2 型糖尿病有关,还与心血管疾病、肌肉骨骼疾病和某些癌症有关,这也导致医疗费用增加和生活质量下降。许多研究将肠道变化与肥胖症的发展联系起来。肠道微生物组成的有害变化——肠道菌群失调,导致肠道通透性改变,与肥胖和 2 型糖尿病有关。许多因素会影响肠道微生物群的内稳态,包括饮食、遗传、昼夜节律、药物、益生菌和抗生素。此外,减重手术会引起肠道微生物群的变化,这有助于解释手术后观察到的代谢益处。目前的肥胖症管理策略包括饮食干预、运动、药物治疗和减重手术,新兴的治疗方法包括改变肠道微生物群的方法,显示出有希望的疗效。虽然近年来药物治疗取得了显著进展,但减重手术仍然是最有效的可持续减肥治疗方法之一。然而,这种方法的获得通常仅限于那些患有严重肥胖症的人。这突显出需要非手术干预,特别是对于青少年和轻度肥胖患者。在这篇全面的综述中,我们评估了两种目前最有效的抗肥胖治疗方法——药物治疗和减重手术——对肠道微生物群组成和功能的长期改变。此外,我们还强调了肠道微生物群的功能,重点介绍了特定细菌、其代谢物以及调节肠道微生物群以预防和治疗肥胖的策略。本综述旨在深入了解肥胖症管理的发展趋势以及基于微生物组的方法在应对这一紧迫的全球健康挑战方面的潜力。